结直肠癌是全球最常见的恶性肿瘤，奥沙利铂作为新型铂类抗癌药的广泛应用显著提高了结直肠癌患者的生存率，但化疗耐药性使其疗效受限，导致预后不良。近年来，越来越多的证据表明长链非编码RNA（lncRNA）在产生药物抵抗过程中发挥不可替代的作用，特异性lncRNA可作为结直肠癌的新型治疗靶点和生物标志物。归纳总结了lncRNA参与奥沙利铂耐药的调节通路，lncRNA的调控可能为研究新型的结直肠癌治疗药物提供线索，提高耐药患者的治疗效果，改善临床疗效。

Colorectal cancer is the most common malignant tumor in the world. The widespread application of oxaliplatin as a new type of platinum-based anticancer drug has significantly improved the survival rate of patients with colorectal cancer, but the chemotherapy resistance has greatly reduced the efficacy of the drug and led to poor prognosis. In recent years, more and more evidence has shown that long non-coding RNAs (lncRNAs) play an irreplaceable role in the process of drug resistance, and specific lncrnas can be used as novel therapeutic targets and biomarkers for colorectal cancer. The regulation pathway of lncRNA involved in oxaliplatin resistance was summarized. The regulation of lncRNA may provide clues for the study of novel colorectal cancer treatment drugs, improve the therapeutic effect of drug-resistant patients, and improve the clinical efficacy.

R965.3；R969.4

2022年内蒙古医科大学面上项目（YKD2022MS016）